139 related articles for article (PubMed ID: 38113467)
1. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Enshaei A; Joy M; Butler E; Kirkwood AA; Messina M; Pavoni C; Morgades M; Harrison CJ; Foà R; Ribera JM; Chiaretti S; Bassan R; Fielding AK; Moorman AV
Blood Adv; 2024 Mar; 8(5):1155-1166. PubMed ID: 38113467
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols.
Ampatzidou M; Papadhimitriou SI; Paisiou A; Paterakis G; Tzanoudaki M; Papadakis V; Florentin L; Polychronopoulou S
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174980
[TBL] [Abstract][Full Text] [Related]
5. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Sanz MA; Lo Coco F; Martín G; Avvisati G; Rayón C; Barbui T; Díaz-Mediavilla J; Fioritoni G; González JD; Liso V; Esteve J; Ferrara F; Bolufer P; Bernasconi C; Gonzalez M; Rodeghiero F; Colomer D; Petti MC; Ribera JM; Mandelli F
Blood; 2000 Aug; 96(4):1247-53. PubMed ID: 10942364
[TBL] [Abstract][Full Text] [Related]
6. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
7. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
[TBL] [Abstract][Full Text] [Related]
8. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
9. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
10. Participatory Heuristic Evaluation of the Second Iteration of the eWALL Interface Application.
Hangaard S; Schaarup C; Hejlesen OK
Stud Health Technol Inform; 2016; 228():599-603. PubMed ID: 27577454
[TBL] [Abstract][Full Text] [Related]
11. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL.
Giebel S; Thomas X; Hallbook H; Geissler K; Boiron JM; Huguet F; Koller E; Jaeger U; Smedmyr B; Hellmann A; Holowiecki J
Eur J Cancer; 2012 Feb; 48(3):360-7. PubMed ID: 22196969
[TBL] [Abstract][Full Text] [Related]
12. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
13. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
Front Oncol; 2020; 10():577. PubMed ID: 32391267
[No Abstract] [Full Text] [Related]
14. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Network-Based Analysis of Colorectal Cancer Identifies Novel Prognostic Factors and an Integrative Prognostic Index.
Hou X; He X; Wang K; Hou N; Fu J; Jia G; Zuo X; Xiong H; Pang M
Cell Physiol Biochem; 2018; 49(5):1703-1716. PubMed ID: 30248669
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(7):1-52. PubMed ID: 27099643
[TBL] [Abstract][Full Text] [Related]
17. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
18. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Marks DI; Kirkwood AA; Rowntree CJ; Aguiar M; Bailey KE; Beaton B; Cahalin P; Castleton AZ; Clifton-Hadley L; Copland M; Goldstone AH; Kelly R; Lawrie E; Lee S; McMillan AK; McMullin MF; Menne TF; Mitchell RJ; Moorman AV; Patel B; Patrick P; Smith P; Taussig D; Yallop D; Alapi KZ; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e262-e275. PubMed ID: 35358441
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
